Journal Mobile Options
Table of Contents
Vol. 132, No. 1-2, 2011
Issue release date: November 2010
Cytogenet Genome Res 2011;132:16–21

Two New Cases of Polysomy 13 in Canine Prostate Cancer

Reimann-Berg N. · Willenbrock S. · Murua Escobar H. · Eberle N. · Gerhauser I. · Mischke R. · Bullerdiek J. · Nolte I.
aSmall Animal Clinic and Research Cluster REBIRTH, University of Veterinary Medicine Hannover, Hannover, bCenter for Human Genetics, University of Bremen, Bremen, cDepartment of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Besides man, the dog is the only known mammalian species that spontaneously develops carcinomas of the prostate with considerable frequency. For this reason, the dog is considered to be the only useful animal model for spontaneously occurring prostate malignancies in man. Cytogenetic investigations of human prostate cancers have revealed the frequent occurrence of trisomies 7, 8, and 17. Chromosome analyses of canine prostate carcinomas are rare. In this report we present 2 cases of canine prostate cancer showing a clonal polysomy 13 along with complex karyotype changes. Along with a previous report demonstrating polysomy 13 as the only karyotype deviation in a canine prostate cancer the present report supports the hypothesis that in canine prostate cancer, polysomy 13 is a recurrent cytogenetic aberration linked to the development of the disease. As human chromosomes (HSA) 8q and 4q and the canine chromosome (CFA) 13 share high homology, these results suggest that a conserved area on these chromosomes is involved in tumorigenesis in both species.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, et al: Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 77:437–448 (1997).
  2. Bartnitzke S, Motzko H, Caselitz J, Kornberg M, Bullerdiek J, Schloot W: A recurrent marker chromosome involving chromosome 1 in two mammary tumors of the dog. Cytogenet Cell Genet 60:135–137 (1992).
  3. Breen M: Canine cytogenetics – from band to basepair. Cytogenet Genome Res 120:50–60 (2008).
  4. Breen M, Thomas R, Binns MM, Carter N, Langford C: Reciprocal chromosome painting reveals detailed regions of conserved synteny between the karyotypes of the domestic dog (Canis familiaris) and human. Genomics 61:145–155 (1999).
  5. Bullerdiek J, Böschen C, Bartnitzke S: Aberrations of chromosome 8 in mixed salivary gland tumors – cytogenetic findings on seven cases. Cancer Genet Cytogenet 24:205–212 (1987).
  6. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, et al: Clinical and pathological aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate 45:173–183 (2000).
  7. Di Lorenzo G, Autorino R, D’ Armiento FP, Mignogna C, De Laurentis M, et al: Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 30:987–992 (2004).
  8. Etem E, Elyas H, Yüce H, Akpolat N, Atikeler MK: Importance of chromosome 8 gain and c-myc gene amplification in high grade prostate cancer. Firat Üniversitesi Saglik Bilgi Dergisi 18:157–162 (2004).
  9. Hahn KA, Richardson RC, Hahn EA, Chrisman CL: Diagnostic and prognostic importance of chromosomal aberrations identified in 61 dogs with lymphosarcoma. Vet Path 31:528–540 (1994).
  10. Hörsting N, Reimann N, Bartnitzke S, Bullerdiek J, Wohlsein P, Nolte I: Cytogenetic analysis of three oropharyngeal malignant melanomas in dogs. Res Vet Sci 67:149–151 (1999).
  11. Karashima T, Taguchi T, Yoshikawa C, Kamada M, Kasahara K, et al: Numerical chromosomal changes in metastatic prostate cancer following anti-androgen therapy: fluorescence in situ hybridisation analysis of 5 Japanese cases. Cancer Genet Cytogenet 120:148–154 (2000).
  12. Lin D, Watahiki A, Bayani J, Zhang F, Liu L, et al: ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res 68:4352–4359 (2008).
  13. Maini A, Archer C, Wang CY, Haas GP: Comparative pathology of benign prostatic hyperplasia and prostate cancer. In Vivo 11:293–299 (1997).
  14. Mark HF, Feldmann D, Das S, Samy M, Sun CL, Mark S: Assessment of chromosomal trisomies in prostate cancer using fluorescent in situ hybridization. Exp Mol Path 67:109–117 (1999).
  15. Mayr B, Schleger W, Kalat M, Schweiger P, Reifinger M, Eisenmenger E: Cytogenetic studies in a canine mammary tumor. Cancer Genet Cytogenet 47:83–87 (1990).
  16. Reimann N, Rogalla P, Kazmierczak B, Bonk U, Nolte I, et al: Evidence that metacentric and submetacentric chromosomes in canine tumors can result from telomeric fusions. Cytogenet Cell Genet 67:81–85 (1994).
  17. Reimann N, Bartnitzke S, Bullerdiek J, Schmitz U, Rogalla P, et al: An extended nomenclature of the canine karyotype. Cytogenet Cell Genet 73:140–144 (1996).
  18. Reimann N, Bartnitzke S, Nolte I, Bullerdiek J: Working with canine chromosomes: current recommendations for karyotype description. J Hered 90:31–34 (1999a).
  19. Reimann N, Nolte I, Bartnitzke S, Bullerdiek J: Re: Sit, DNA, sit: cancer genetics going to the dogs. J Natl Cancer Inst 91:1688–1689 (1999b).
  20. Rommel B, Hutter KJ, Bullerdiek J, Bartnitzke S, Goerttler K, Schloot W: Identification of flow-sorted chromosomes by G-banding and in situ hybridization. Cytometry 9:504–507 (1988).
  21. Seabright M: A rapid banding technique for human chromosomes. Lancet I:971–972 (1971).

    External Resources

  22. Skacel M, Ormsby AH, Pettay JD, Tsiftsakis EK, Liou LS, et al: Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum Path 32:1392–1397 (2001).
  23. Steiner T, Junker K, Burkhardt F, Braunsdorf A, Janitzky V, Schubert J: Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer. Eur Urol 41:167–171 (2002).
  24. Switonski M, Reimann N, Bosma AA, Long S, Bartnitzke S, et al: Report on the progress of standardization of the G-banded canine (Canis familiaris) karyotype. Chrom Res 4:306–309 (1996).
  25. Thomas R, Smith KC, Ostrander EA, Galibert F, Breen M: Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Brit J Cancer 89:1530–1537 (2003).
  26. Van Dekken H, Alers JC, Damen IA, Vissers KJ, Kritjenburg PJ, et al: Genetic evaluation of localized prostate cancer in a cohort of forty patients: a gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest 83:789–796 (2003).
  27. Verma RS, Manikal M, Conte RA, Godec CJ: Chromosomal basis of adenocarcinoma of the prostate. Cancer Investigation 17:441–447 (1999).
  28. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, et al: Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 36:64–67 (1998).
  29. Winkler S, Murua Escobar H, Eberle N, Reimann-Berg N, Nolte I, Bullerdiek J: Establishment of a cell line derived from a canine prostate carcinoma with a highly rearranged karyotype. J Hered 96:782–785 (2005).
  30. Winkler S, Reimann-Berg N, Murua Escobar H, Loeschke S, Eberle N, et al: Polysomy 13 in a canine prostate carcinoma underlining its significance in the development of prostate cancer. Cancer Genet Cytogenet 169:154–158 (2006).
  31. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, et al: c-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia 10:995–1003 (2008).

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50